Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group. Holloway RG, et al. Arch Neurol. 2004 Jul;61(7):1044-53. doi: 10.1001/archneur.61.7.1044. Arch Neurol. 2004. PMID: 15262734 Clinical Trial.
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease.
Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, Marshall F, Shoulson I, Eberly S, Walker F, Factor S, Hunt V, Shinaman A, Jankovic J. Frank S, et al. Clin Neuropharmacol. 2008 May-Jun;31(3):127-33. doi: 10.1097/WNF.0b013e3180ca77ea. Clin Neuropharmacol. 2008. PMID: 18520979 Clinical Trial.
Fear of health insurance loss among individuals at risk for Huntington disease.
Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K; Huntington Study Group PHAROS Investigators. Oster E, et al. Am J Med Genet A. 2008 Aug 15;146A(16):2070-7. doi: 10.1002/ajmg.a.32422. Am J Med Genet A. 2008. PMID: 18627059 Free PMC article. Clinical Trial.
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.
Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators. Schobel SA, et al. Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15. Neurology. 2017. PMID: 29142089 Free PMC article. Clinical Trial.
Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Parashos SA, et al. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391. JAMA Neurol. 2014. PMID: 24711047 Free PMC article. Clinical Trial.
Copy number variation in familial Parkinson disease.
Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Pankratz N, et al. PLoS One. 2011;6(8):e20988. doi: 10.1371/journal.pone.0020988. Epub 2011 Aug 2. PLoS One. 2011. PMID: 21829596 Free PMC article.
Challenges assessing clinical endpoints in early Huntington disease.
Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, Moser D, Williams JK, Simpson S, Langbehn D, van Kammen DP; PREDICT-HD Investigators of the Huntington Study Group. Paulsen JS, et al. Mov Disord. 2010 Nov 15;25(15):2595-603. doi: 10.1002/mds.23337. Mov Disord. 2010. PMID: 20623772 Free PMC article.
21 results
Jump to page
Feedback